CoChat
Sign Up
Cited by 147

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Tumour predisposition and cancer syndromes as models to study gene–environment interactions

Carbone, Michele, Arron, Sarah T., Beutler, Bruce, Bononi, Angela, Cavenee, Webster, Cleaver, James E., Croce, Carlo M., D’Andrea, Alan, Foulkes, William D., Gaudino, Giovanni, Groden, Joanna L., Henske, Elizabeth P., Hickson, Ian D., Hwang, Paul M., Kolodner, Richard D., Mak, Tak W., Malkin, David, Monnat, Raymond J., Novelli, Flavia, Pass, Harvey I., Petrini, John H., Schmidt, Laura S., Yang, Haining·2020·Nature Reviews Cancer
DOI 10.1038/s41568-020-0265-yPMC PMC8104546
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41568-020-0265-y

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 182

  1. Tomasetti, C. & Vogelstein, B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78–81 (2015). · DOI · Paper page
  2. Tomasetti, C., Li, L. & Vogelstein, B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 355, 1330–1334 (2017). · DOI
  3. Wu, S., Powers, S., Zhu, W. & Hannun, Y. A. Substantial contribution of extrinsic risk factors to cancer development. Nature 529, 43–47 (2016). · DOI
  4. Wu, S., Zhu, W., Thompson, P. & Hannun, Y. A. Evaluating intrinsic and non-intrinsic cancer risk factors. Nat. Commun. 9, 3490 (2018).
  5. Carbone, M., Klein, G., Gruber, J. & Wong, M. Modern criteria to establish human cancer etiology. Cancer Res. 64, 5518–5524 (2004). · DOI
  6. Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018). · DOI · Paper page
  7. Huang, K. L. et al. Pathogenic germline variants in 10,389 adult cancers. Cell 173, 355–370 e314 (2018). · DOI
  8. Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302–308 (2014). · DOI
  9. McGee, R. B. & Nichols, K. E. Introduction to cancer genetic susceptibility syndromes. Hematol. Am. Soc. Hematol Educ. Program 2016, 293–301 (2016). · DOI
  10. Carbone, M. et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat. Rev. Cancer 7, 147–154 (2007). · DOI
  11. Emri, S. A. The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad. Ann. Transl Med. 5, 239 (2017). · DOI
  12. Baumann, F., Ambrosi, J. P. & Carbone, M. Asbestos is not just asbestos: an unrecognised health hazard. Lancet. Oncol. 14, 576–578 (2013). · DOI
  13. Alpert, N., Gerwen, Mv. & Taioli, E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. https://doi.org/10.21037/tlcr.2019.11.11 (2019). · DOI
  14. Carbone, M. et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J. Clin. 69, 402–429 (2019). · DOI · Paper page
  15. Sluis-Cremer, G. K., Liddell, F. D., Logan, W. P. & Bezuidenhout, B. N. The mortality of amphibole miners in South Africa, 1946–80. Br. J. Ind. Med. 49, 566–575 (1992).
  16. Carbone, M. et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc. Natl Acad. Sci. USA 108, 13618–13623 (2011). · DOI · Paper page
  17. Roushdy-Hammady, I., Siegel, J., Emri, S., Testa, J. R. & Carbone, M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357, 444–445 (2001). · DOI
  18. Carbone, M. et al. BAP1 and cancer. Nat. Rev. Cancer 13, 153–159 (2013). · DOI · Paper page
  19. Carbone, M. et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl Med. 10, 179 (2012). · DOI
  20. Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022–1025 (2011). · DOI · Paper page
  21. Abdel-Rahman, M. H. et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48, 856–859 (2011). · DOI
  22. Yu, M. D., Masoomian, B., Shields, J. A. & Shields, C. L. BAP1 germline mutation associated with bilateral primary uveal melanoma. Ocular Oncol. Pathol. 6, 10–14 (2020). · DOI
  23. Farley, M. N. et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol. Cancer Res. 11, 1061–1071 (2013). · DOI
  24. Carbone, M. et al. Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s. PLoS Genet. 11, e1005633 (2015). · DOI
  25. Yoshikawa, Y., Emi, M., Nakano, T. & Gaudino, G. Mesothelioma developing in carriers of inherited genetic mutations. Transl Lung Cancer Res. 9 (Suppl. 1), S67–S76 (2019).
  26. Haugh, A. M. et al. Genotypic and phenotypic features of BAP1 cancer syndrome: a report of 8 new families and review of cases in the literature. JAMA Dermatol. 153, 999–1006 (2017). · DOI
  27. Walpole, S. et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J. Natl Cancer Inst. 110, 1328–1341 (2018). · DOI
  28. Bononi, A. et al. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature 546, 549–553 (2017). · DOI
  29. Napolitano, A. et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35, 1996–2002 (2016). · DOI
  30. Kadariya, Y. et al. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res. 76, 2836–2844 (2016). · DOI
  31. Hickson, I. D. RecQ helicases: caretakers of the genome. Nat. Rev. Cancer 3, 169–178 (2003). · DOI
  32. Oshima, J., Sidorova, J. M. & Jr. Monnat, R. J. Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. Ageing Res. Rev. 33, 105–114 (2017). · DOI
  33. Killen, M. W., Stults, D. M., Adachi, N., Hanakahi, L. & Pierce, A. J. Loss of Bloom syndrome protein destabilizes human gene cluster architecture. Hum. Mol. Genet. 18, 3417–3428 (2009). · DOI
  34. Moser, M. J. et al. Genetic instability and hematologic disease risk in Werner syndrome patients and heterozygotes. Cancer Res. 60, 2492–2496 (2000).
  35. Lauper, J. M., Krause, A., Vaughan, T. L. & Jr. Monnat, R. J. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS One 8, e59709 (2013). · DOI
  36. German, J. Bloom’s syndrome. XX. The first 100 cancers. Cancer Genet. Cytogenet. 93, 100–106 (1997). · DOI
  37. Gruber, S. B. et al. BLM heterozygosity and the risk of colorectal cancer. Science 297, 2013 (2002). · DOI
  38. Goss, K. H. et al. Enhanced tumor formation in mice heterozygous for Blm mutation. Science 297, 2051–2053 (2002). · DOI
  39. Yao, Y. & Dai, W. Genomic instability and cancer. J. Carcinog. Mutagen. 5, 1000163 (2014).
  40. Yang, H. et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis. 6, e1786 (2015).
  41. Kolodner, R. D. A personal historical view of DNA mismatch repair with an emphasis on eukaryotic DNA mismatch repair. DNA Repair. 38, 3–13 (2016). · DOI
  42. Graham, V. W. J., Putnam, C. D. & Kolodner, R. D. DNA mismatch repair: mechanisms and cancer genetics. Encycl. Cancer 1, 530–538 (2019).
  43. Giorgi, C. et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 330, 1247–1251 (2010). · DOI
  44. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891–899 (2004). · DOI · Paper page
  45. Kastenhuber, E. R. & Lowe, S. W. Putting p53 in context. Cell 170, 1062–1078 (2017). · DOI · Paper page
  46. Yu, H. et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc. Natl Acad. Sci. USA 111, 285–290 (2014). · DOI
  47. Giorgi, C., Bonora, M. & Pinton, P. Inside the tumor: p53 modulates calcium homeostasis. Cell Cycle 14, 933–934 (2015). · DOI
  48. Zhang, Y. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol. 20, 1181–1192 (2018). · DOI
  49. Wang, P. Y. et al. Increased oxidative metabolism in the Li-Fraumeni syndrome. N. Engl. J. Med. 368, 1027–1032 (2013). · DOI
  50. Bononi, A. et al. Germline BAP1 mutations induce a Warburg effect. Cell Death Differ. 24, 1694–1704 (2017). · DOI · Paper page
  51. Villani, A. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 17, 1295–1305 (2016). · DOI · Paper page
  52. Mai, P. L. et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122, 3673–3681 (2016). · DOI
  53. Gonzalez, K. D. et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J. Med. Genet. 46, 689–693 (2009). · DOI
  54. Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410–1413 (2010). · DOI
  55. Yoshikawa, Y. et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc. Natl Acad. Sci. USA 113, 13432–13437 (2016). · DOI
  56. Nasu, M. et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J. Thorac. Oncol. 10, 565–576 (2015). · DOI
  57. Jin, S. et al. Comprehensive analysis of BAP1 somatic mutation in clear cell renal cell carcinoma to explore potential mechanisms in Silico. J. Cancer 9, 4108–4116 (2018). · DOI
  58. Pena-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 44, 751–759 (2012). · DOI
  59. Malkin, D. Li-fraumeni syndrome. Genes Cancer 2, 475–484 (2011). · DOI
  60. Mashtalir, N. et al. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol. Cell 54, 392–406 (2014). · DOI
  61. Bhattacharya, S., Hanpude, P. & Maiti, T. K. Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: a new insight in enzymatic inactivation. Sci. Rep. 5, 18462 (2015).
  62. Heymann, S. et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat. Oncol. 5, 104 (2010). · DOI
  63. Marsella, J. M., Liu, B. L., Vaslet, C. A. & Kane, A. B. Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. Env. Health Perspect. 105 (Suppl. 5), 1069–1072 (1997). · DOI
  64. De Flora, S. et al. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke. Cancer Res. 63, 793–800 (2003).
  65. Boyle, J. M. et al. Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families. Br. J. Cancer 77, 2181–2192 (1998). · DOI
  66. Hajkova, N. et al. Germline mutation in the TP53 gene in uveal melanoma. Sci. Rep. 8, 7618 (2018). · DOI
  67. Jiang, W., Ananthaswamy, H. N., Muller, H. K. & Kripke, M. L. p53 protects against skin cancer induction by UV-B radiation. Oncogene 18, 4247–4253 (1999). · DOI
  68. Ford, J. M. & Hanawalt, P. C. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc. Natl Acad. Sci. USA 92, 8876–8880 (1995). · DOI
  69. Kemp, C. J., Wheldon, T. & Balmain, A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 8, 66–69 (1994). · DOI
  70. Nutting, C. et al. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin. Oncol. 12, 300–304 (2000).
  71. Hwang, S. J. et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum. Genet. 113, 238–243 (2003). · DOI
  72. Zhang, Z. et al. A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents Taxol or Adriamycin. Cancer Res. 60, 901–907 (2000).
  73. Krais, A. M. et al. The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53+/+, Trp53+/− and Trp53−/− mice. Arch. Toxicol. 90, 839–851 (2016). · DOI
  74. Tsutsui, T. et al. Aflatoxin B1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndrome. Carcinogenesis 16, 25–34 (1995). · DOI
  75. Cleaver, J. E. & Revet, I. Clinical implications of the basic defects in Cockayne syndrome and xeroderma pigmentosum and the DNA lesions responsible for cancer, neurodegeneration and aging. Mech. Ageing Dev. 129, 492–497 (2008). · DOI
  76. Zheng, C. L. et al. Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes. Cell Rep. 9, 1228–1234 (2014). · DOI
  77. Fujiwara, Y., Ichihashi, M., Kano, Y., Goto, K. & Shimuzu, K. A new human photosensitive subject with a defect in the recovery of DNA synthesis after ultraviolet-light irradiation. J. Investig. Dermatol. 77, 256–263 (1981). · DOI
  78. Cleaver, J. E. et al. Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage. Proc. Natl Acad. Sci. USA 111, 13487–13492 (2014). · DOI · Paper page
  79. Crossley, M. P., Bocek, M. & Cimprich, K. A. R-loops as cellular regulators and genomic threats. Mol. Cell 73, 398–411 (2019). · DOI
  80. Cleaver, J. E. Transcription coupled repair deficiency protects against human mutagenesis and carcinogenesis: personal reflections on the 50th anniversary of the discovery of xeroderma pigmentosum. DNA Repair. 58, 21–28 (2017). · DOI
  81. Cleaver, J. E. Normal reconstruction of DNA supercoiling and chromatin structure in Cockayne syndrome cells during repair of damage from ultraviolet light. Am. J. Hum. Genet. 34, 566–575 (1982).
  82. Parris, C. H. & Kraemer, K. H. Ultraviolet-light induced mutations in Cockayne syndrome cells are primarily caused by cyclobutane dimer photoproducts while repair of other photoproducts is normal. Proc. Natl Acad. Sci. USA 90, 7260–7264 (1993). · DOI · Paper page
  83. Berg, R. J. et al. Impact of global genome repair versus transcription-coupled repair on ultraviolet carcinogenesis in hairless mice. Cancer Res. 60, 2858–2863 (2000).
  84. van Zeeland, A. A. et al. Transcription-coupled repair: impact on UV-induced mutagenesis in cultured rodent cells and mouse skin tumors. Mutat. Res. 577, 170–178 (2005). · DOI
  85. Lynch, H. T., Snyder, C. L., Shaw, T. G., Heinen, C. D. & Hitchins, M. P. Milestones of Lynch syndrome: 1895–2015. Nat. Rev. Cancer 15, 181–194 (2015). · DOI
  86. Jiricny, J. & Nystrom-Lahti, M. Mismatch repair defects in cancer. Curr. Opin. Genet. Dev. 10, 157–161 (2000). · DOI
  87. Srivatsan, A., Bowen, N. & Kolodner, R. D. Mispair-specific recruitment of the Mlh1-Pms1 complex identifies repair substrates of the Saccharomyces cerevisiae Msh2-Msh3 complex. J. Biol. Chem. 289, 9352–9364 (2014). · DOI
  88. Amin, N. S., Nguyen, M. N., Oh, S. & Kolodner, R. D. exo1-Dependent mutator mutations: model system for studying functional interactions in mismatch repair. Mol. Cell Biol. 21, 5142–5155 (2001). · DOI
  89. Boland, P. M., Yurgelun, M. B. & Boland, C. R. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J. Clin. 68, 217–231 (2018). · DOI
  90. Lynch, H. T. & de la Chapelle, A. Genetic susceptibility to non-polyposis colorectal cancer. J. Med. Genet. 36, 801–818 (1999).
  91. Wei, W. et al. Racial differences in MLH1 and MSH2 mutation: an analysis of yellow race and white race based on the InSiGHT database. J. Bioinform Comput. Biol. 8 (Suppl. 1), 111–125 (2010). · DOI
  92. Park, H. M. et al. Colorectal cancer incidence in 5 Asian countries by subsite: an analysis of cancer incidence in five continents (1998–2007). Cancer Epidemiol. 45, 65–70 (2016). · DOI
  93. Diergaarde, B. et al. Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. Clin. Gastroenterol. Hepatol. 5, 736–742 (2007). · DOI
  94. Gingras, D. & Beliveau, R. Colorectal cancer prevention through dietary and lifestyle modifications. Cancer Microenviron. 4, 133–139 (2011). · DOI
  95. Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081–2087 (2011). · DOI
  96. Burn, J., Mathers, J. C. & Bishop, D. T. Chemoprevention in Lynch syndrome. Fam. Cancer 12, 707–718 (2013). · DOI
  97. Niraj, J., Farkkila, A. & D’Andrea, A. D. The Fanconi anemia pathway in cancer. Annu. Rev. Cancer Biol. 3, 457–478 (2019). · DOI
  98. Rodriguez, A. & D’Andrea, A. Fanconi anemia pathway. Curr. Biol. 27, R986–R988 (2017). · DOI
  99. Garaycoechea, J. I. et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 489, 571–575 (2012). · DOI
  100. Langevin, F., Crossan, G. P., Rosado, I. V., Arends, M. J. & Patel, K. J. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 475, 53–58 (2011). · DOI
  101. Kutler, D. I. et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J. Natl Cancer Inst. 95, 1718–1721 (2003). · DOI
  102. van Zeeburg, H. J., Snijders, P. J., Joenje, H. & Brakenhoff, R. H. Re: human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J. Natl Cancer Inst. 96, 968 (2004). · DOI
  103. Hira, A. et al. Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood 122, 3206–3209 (2013). · DOI
  104. Tyburczy, M. E. et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum. Mol. Genet. 23, 2023–2029 (2014). · DOI
  105. Henske, E. P., Jozwiak, S., Kingswood, J. C., Sampson, J. R. & Thiele, E. A. Tuberous sclerosis complex. Nat. Rev. Dis. Prim. 2, 16035 (2016). · DOI
  106. Yeung, R. S. et al. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc. Natl Acad. Sci. USA 91, 11413–11416 (1994). · DOI
  107. Cook, J. D. et al. Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. Proc. Natl Acad. Sci. USA 102, 8644–8649 (2005). · DOI
  108. Nickerson, M. L. et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2, 157–164 (2002). · DOI
  109. Schmidt, L. S. & Linehan, W. M. Molecular genetics and clinical features of Birt-Hogg-Dube syndrome. Nat. Rev. Urol. 12, 558–569 (2015). · DOI
  110. de Kock, L., Wu, M. K. & Foulkes, W. D. Ten years of DICER1 mutations: provenance, distribution, and associated phenotypes. Hum. Mutat. 40, 1939–1953 (2019). · DOI
  111. Miniati, D. N. et al. Prenatal presentation and outcome of children with pleuropulmonary blastoma. J. Pediatr. Surg. 41, 66–71 (2006). · DOI
  112. Kurzynska-Kokorniak, A. et al. The many faces of Dicer: the complexity of the mechanisms regulating Dicer gene expression and enzyme activities. Nucleic Acids Res. 43, 4365–4380 (2015). · DOI
  113. Gross, T. J. et al. A microRNA processing defect in smokers’ macrophages is linked to SUMOylation of the endonuclease DICER. J. Biol. Chem. 289, 12823–12834 (2014). · DOI
  114. Taeubner, J. et al. Penetrance and expressivity in inherited cancer predisposing syndromes. Trends Cancer 4, 718–728 (2018). · DOI · Paper page
  115. Petljak, M. & Alexandrov, L. B. Understanding mutagenesis through delineation of mutational signatures in human cancer. Carcinogenesis 37, 531–540 (2016). · DOI · Paper page
  116. Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517–525 (2017). · DOI · Paper page
  117. Castellsague, E. et al. Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures. Hum. Mutat. 40, 36–41 (2019). · DOI
  118. Polak, P. et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat. Genet. 49, 1476–1486 (2017). · DOI · Paper page
  119. Kucab, J. E. et al. A compendium of mutational signatures of environmental agents. Cell 177, 821–836 (2019). · DOI · Paper page
  120. Wild, C. P., Scalbert, A. & Herceg, Z. Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Env. Mol. Mutagen. 54, 480–499 (2013). · DOI
  121. Nik-Zainal, S. et al. The genome as a record of environmental exposure. Mutagenesis 30, 763–770 (2015).
  122. Herceg, Z. et al. Roadmap for investigating epigenome deregulation and environmental origins of cancer. Int. J. Cancer 142, 874–882 (2018). · DOI
  123. Siddeek, B., Mauduit, C., Simeoni, U. & Benahmed, M. Sperm epigenome as a marker of environmental exposure and lifestyle, at the origin of diseases inheritance. Mutat. Res. 778, 38–44 (2018). · DOI
  124. Johansson, A. et al. Epigenome-wide association study for lifetime estrogen exposure identifies an epigenetic signature associated with breast cancer risk. Clin. Epigenetics 11, 66 (2019). · DOI
  125. Martin, E. M. & Fry, R. C. Environmental Influences on the epigenome: exposure- associated DNA methylation in human populations. Annu. Rev. Public. Health 39, 309–333 (2018). · DOI
  126. Degasperi, A. et al. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat. Cancer 1, 249–263 (2020). · DOI · Paper page
  127. Turnbull, C. et al. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ 361, k1687 (2018). · DOI
  128. Elliott, P., Peakman, T. C. & Biobank, U. K. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 37, 234–244 (2008). · DOI
  129. Manolio, T. A. et al. New models for large prospective studies: is there a better way? Am. J. Epidemiol. 175, 859–866 (2012). · DOI
  130. Sullivan, F., McKinstry, B. & Vasishta, S. The “All of Us” research program. N. Engl. J. Med. 381, 1883–1884 (2019). · DOI
  131. Moresco, E. M., Li, X. & Beutler, B. Going forward with genetics: recent technological advances and forward genetics in mice. Am. J. Pathol. 182, 1462–1473 (2013). · DOI
  132. Arnold, C. N. et al. ENU-induced phenovariance in mice: inferences from 587 mutations. BMC Res. Notes 5, 577 (2012). · DOI
  133. Wang, T. et al. Real-time resolution of point mutations that cause phenovariance in mice. Proc. Natl Acad. Sci. USA 112, E440–E449 (2015). · DOI
  134. Mager, L. F. et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J. Clin. Invest. 125, 2579–2591 (2015). · DOI
  135. de Vos tot Nederveen Cappel, W. H. et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis. Colon. Rectum 45, 1588–1594 (2002). · DOI
  136. Jarvinen, H. J. et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118, 829–834 (2000). · DOI · Paper page
  137. Schmeler, K. M. et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N. Engl. J. Med. 354, 261–269 (2006). · DOI
  138. Lynch, H. T., Snyder, C. L., Lynch, J. F., Riley, B. D. & Rubinstein, W. S. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J. Clin. Oncol. 21, 740–753 (2003). · DOI
  139. Kratz, C. P. et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin. Cancer Res. 23, e38–e45 (2017). · DOI · Paper page
  140. Vogel, W. H. Li-Fraumeni syndrome. J. Adv. Pract. Oncol. 8, 742–746 (2017).
  141. Pastorino, S. et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J. Clin. Oncol. 36, 3485–3494 (2018). · DOI
  142. Baumann, F. et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36, 76–81 (2015). · DOI
  143. Kobrinski, D. A., Yang, H. & Kittaneh, M. BAP1: role in carcinogenesis and clinical implications. Transl Lung Cancer Res. 9 (Suppl. 1), S60–S66 (2019).
  144. Wang, P. Y. et al. Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J. Clin. Invest. 127, 132–136 (2017). · DOI
  145. Achatz, M. I., Hainaut, P. & Ashton-Prolla, P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol. 10, 920–925 (2009). · DOI
  146. Achatz, M. I. & Zambetti, G. P. The inherited p53 mutation in the Brazilian population. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a026195 (2016). · DOI
  147. DiGiammarino, E. L. et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat. Struct. Biol. 9, 12–16 (2002). · DOI
  148. Park, J. H. et al. Mouse homolog of the human TP53 R337H mutation reveals its role in tumorigenesis. Cancer Res. 78, 5375–5383 (2018). · DOI
  149. Macedo, G. S. et al. Increased oxidative damage in carriers of the germline TP53 p.R337H mutation. PLoS One 7, e47010 (2012).
  150. Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A. & D’Andrea, A. D. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 7, 675–693 (2017). · DOI
  151. Reuter, S., Gupta, S. C., Chaturvedi, M. M. & Aggarwal, B. B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. 49, 1603–1616 (2010). · DOI · Paper page
  152. Craven, P. A. & DeRubertis, F. R. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis 13, 541–546 (1992). · DOI
  153. Sheng, H. et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99, 2254–2259 (1997). · DOI
  154. Barnes, C. J. & Lee, M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114, 873–877 (1998). · DOI
  155. Beck, S. L. Effects of aspirin on colorectal cancer related to lynch syndrome. J. Adv. Pract. Oncol. 3, 395–398 (2012).
  156. Franz, D. N. et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One 11, e0158476 (2016).
  157. Yoshida, K. et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature 578, 266–272 (2020). · DOI
  158. Merlino, G. & Noonan, F. P. Modeling gene-environment interactions in malignant melanoma. Trends Mol. Med. 9, 102–108 (2003). · DOI
  159. Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in Malignant Mesothelioma. J. Clin. Oncol. 36, 2863–2871 (2018). · DOI
  160. Hassan, R. et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc. Natl Acad. Sci. USA 116, 9008–9013 (2019). · DOI
  161. Guerin, A. et al. IRF4 haploinsufficiency in a family with Whipple’s disease. eLife 7, e32340 (2018). · DOI
  162. Boisson-Dupuis, S. et al. Tuberculosis and impaired IL-23-dependent IFN-gamma immunity in humans homozygous for a common TYK2 missense variant. Sci. Immunol. 3, eaau8714 (2018). · DOI
  163. Cirulli, E. T. et al. Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. Nat. Commun. 11, 542 (2020). · DOI
  164. Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179–204 (2010). · DOI · Paper page
  165. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085–2088 (1998). · DOI · Paper page
  166. Brunkow, M. E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68–73 (2001). · DOI
  167. Warburg, O. On respiratory impairment in cancer cells. Science 124, 269–270 (1956). · DOI
  168. Porporato, P. E., Filigheddu, N., Pedro, J. M. B., Kroemer, G. & Galluzzi, L. Mitochondrial metabolism and cancer. Cell Res. 28, 265–280 (2018). · DOI
  169. Peel, J. B. et al. A prospective study of cardiorespiratory fitness and breast cancer mortality. Med. Sci. Sports Exerc. 41, 742–748 (2009). · DOI
  170. LeBleu, V. S. et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 1001–1015 (2014).
  171. Tan, A. S. et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 21, 81–94 (2015). · DOI · Paper page
  172. Sullivan, L. B., Gui, D. Y. & Vander Heiden, M. G. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat. Rev. Cancer 16, 680–693 (2016). · DOI · Paper page
  173. Gottlieb, E. & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5, 857–866 (2005). · DOI
  174. Sciacovelli, M. & Frezza, C. Oncometabolites: unconventional triggers of oncogenic signalling cascades. Free Radic. Biol. Med. 100, 175–181 (2016). · DOI
  175. Inoue, S. et al. Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2. Cancer Cell 30, 337–348 (2016). · DOI
  176. Nowicki, S. & Gottlieb, E. Oncometabolites: tailoring our genes. FEBS J. 282, 2796–2805 (2015). · DOI
  177. Sabharwal, S. S. & Schumacker, P. T. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat. Rev. Cancer 14, 709–721 (2014). · DOI
  178. Weinberg, C. R., Brown, K. G. & Hoel, D. G. Altitude, radiation, and mortality from cancer and heart disease. Radiat. Res. 112, 381–390 (1987). · DOI
  179. Sung, H. J. et al. Ambient oxygen promotes tumorigenesis. PLoS One 6, e19785 (2011).
  180. Simeonov, K. P. & Himmelstein, D. S. Lung cancer incidence decreases with elevation: evidence for oxygen as an inhaled carcinogen. PeerJ 3, e705 (2014).
  181. Sung, H. J. et al. Mitochondrial respiration protects against oxygen-associated DNA damage. Nat. Commun. 1, 1–8 (2010).
  182. Harris, I. S. et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27, 211–222 (2015). · DOI · Paper page

Cited by

Sorted by citations

See all 147

Metadata

Authors
Carbone, M., Arron, S. T., Beutler, B., Bononi, A., Cavenee, W., Cleaver, J. E., Croce, C. M., D’Andrea, A., Foulkes, W. D., Gaudino, G., Groden, J. L., Henske, E. P., Hickson, I. D., Hwang, P. M., Kolodner, R. D., Mak, T. W., Malkin, D., Monnat, R. J., Novelli, F., Pass, H. I., Petrini, J. H., Schmidt, L. S., & Yang, H.
ORCID
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2020-05-29
Volume
20
Issue
9
Pages
533-549
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/s41568-020-0265-y
PMC
PMC8104546
Cited by
147
References
28
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review